Initial management of cutaneous dermatomyositis
- Ruth Ann Vleugels, MD, MPH
Ruth Ann Vleugels, MD, MPH
- Associate Professor in Dermatology
- Harvard Medical School
Classic dermatomyositis (DM) is an idiopathic inflammatory myopathy that most commonly presents with progressive, symmetric proximal muscle weakness and a group of characteristic cutaneous findings. The cutaneous manifestations of DM may also develop in the absence of detectable muscle disease, and can persist after the successful treatment of DM-associated myositis.
Patients with DM often present with intensely pruritic areas of confluent, violaceous erythema on the scalp, face, upper trunk, and upper extremities. Pruritus can be disabling.
Skin lesions of DM are often resistant to photoprotection and topical therapies alone, necessitating the initiation of antimalarial drugs and/or methotrexate. Patients who fail to respond to these interventions may require more aggressive immunosuppressive or immunomodulatory therapies.
The initial management of the cutaneous manifestations of DM will be discussed here. The treatment of refractory DM, as well as the clinical manifestations, diagnosis, and management of the noncutaneous manifestations of DM and juvenile DM are reviewed elsewhere. (See "Management of refractory cutaneous dermatomyositis" and "Clinical manifestations of dermatomyositis and polymyositis in adults" and "Diagnosis and differential diagnosis of dermatomyositis and polymyositis in adults" and "Initial treatment of dermatomyositis and polymyositis in adults" and "Treatment of recurrent and resistant dermatomyositis and polymyositis in adults" and "Juvenile dermatomyositis and polymyositis: Epidemiology, pathogenesis, and clinical manifestations" and "Juvenile dermatomyositis and polymyositis: Treatment, complications, and prognosis".)
OVERVIEW OF CLINICAL FEATURES
Skin changes associated with dermatomyositis (DM) include pathognomonic findings such as Gottron's papules (violaceous papules overlying interphalangeal and metacarpophalangeal joints) and Gottron's sign (macular violaceous erythema overlying other joints, such as the elbows or knees) (picture 1A-D). Violaceous erythema involving the periorbital skin (heliotrope eruption), scalp, V of the neck, shoulders, extensor surfaces of the upper extremities, upper chest, and upper back are additional characteristic findings in DM (picture 2A-D). Scale may or may not be present, but is typically prominent on the scalp, where it may be accompanied by diffuse alopecia (picture 2E).
- Dourmishev L, Meffert H, Piazena H. Dermatomyositis: comparative studies of cutaneous photosensitivity in lupus erythematosus and normal subjects. Photodermatol Photoimmunol Photomed 2004; 20:230.
- Hundley JL, Carroll CL, Lang W, et al. Cutaneous symptoms of dermatomyositis significantly impact patients' quality of life. J Am Acad Dermatol 2006; 54:217.
- Sontheimer RD. The management of dermatomyositis: current treatment options. Expert Opin Pharmacother 2004; 5:1083.
- Gerami P, Schope JM, McDonald L, et al. A systematic review of adult-onset clinically amyopathic dermatomyositis (dermatomyositis siné myositis): a missing link within the spectrum of the idiopathic inflammatory myopathies. J Am Acad Dermatol 2006; 54:597.
- Jorizzo JL. Dermatomyositis: practical aspects. Arch Dermatol 2002; 138:114.
- Klein RQ, Teal V, Taylor L, et al. Number, characteristics, and classification of patients with dermatomyositis seen by dermatology and rheumatology departments at a large tertiary medical center. J Am Acad Dermatol 2007; 57:937.
- Jorizzo, JL, Carroll, et al. Dermatomyositis. In: Dermatology, Bolognia, JL, Jorizzo, JL, Rapini, RP, et al (Eds), Elsevier Limited, Spain 2008. p.575.
- Oddis CV, Conte CG, Steen VD, Medsger TA Jr. Incidence of polymyositis-dermatomyositis: a 20-year study of hospital diagnosed cases in Allegheny County, PA 1963-1982. J Rheumatol 1990; 17:1329.
- Iorizzo LJ 3rd, Jorizzo JL. The treatment and prognosis of dermatomyositis: an updated review. J Am Acad Dermatol 2008; 59:99.
- Bendewald MJ, Wetter DA, Li X, Davis MD. Incidence of dermatomyositis and clinically amyopathic dermatomyositis: a population-based study in Olmsted County, Minnesota. Arch Dermatol 2010; 146:26.
- Klein RQ, Bangert CA, Costner M, et al. Comparison of the reliability and validity of outcome instruments for cutaneous dermatomyositis. Br J Dermatol 2008; 159:887.
- Yassaee M, Fiorentino D, Okawa J, et al. Modification of the cutaneous dermatomyositis disease area and severity index, an outcome instrument. Br J Dermatol 2010; 162:669.
- Cheong WK, Hughes GR, Norris PG, Hawk JL. Cutaneous photosensitivity in dermatomyositis. Br J Dermatol 1994; 131:205.
- Callen JP. Photosensitivity in collagen vascular diseases. Semin Cutan Med Surg 1999; 18:293.
- Callen JP, Wortmann RL. Dermatomyositis. Clin Dermatol 2006; 24:363.
- Shirani Z, Kucenic MJ, Carroll CL, et al. Pruritus in adult dermatomyositis. Clin Exp Dermatol 2004; 29:273.
- Quain RD, Werth VP. Management of cutaneous dermatomyositis: current therapeutic options. Am J Clin Dermatol 2006; 7:341.
- Yoshimasu T, Ohtani T, Sakamoto T, et al. Topical FK506 (tacrolimus) therapy for facial erythematous lesions of cutaneous lupus erythematosus and dermatomyositis. Eur J Dermatol 2002; 12:50.
- Ueda M, Makinodan R, Matsumura M, Ichihashi M. Successful treatment of amyopathic dermatomyositis with topical tacrolimus. Br J Dermatol 2003; 148:595.
- Lampropoulos CE, D' Cruz DP. Topical tacrolimus treatment in a patient with dermatomyositis. Ann Rheum Dis 2005; 64:1376.
- Hollar CB, Jorizzo JL. Topical tacrolimus 0.1% ointment for refractory skin disease in dermatomyositis: a pilot study. J Dermatolog Treat 2004; 15:35.
- García-Doval I, Cruces M. Topical tacrolimus in cutaneous lesions of dermatomyositis: lack of effect in side-by-side comparison in five patients. Dermatology 2004; 209:247.
- Kim JE, Jeong MG, Lee HE, et al. Successful treatment of cutaneous lesions of dermatomyositis with topical pimecrolimus. Ann Dermatol 2011; 23:348.
- Navarrete-Dechent C, Manríquez JJ, del Puerto C, Vera-Kellet C. Brimonidine gel for the treatment of persistent heliotrope rash in a patient with amyopathic dermatomyositis: a case report. J Eur Acad Dermatol Venereol 2016; 30:476.
- Wallace DJ. The use of chloroquine and hydroxychloroquine for non-infectious conditions other than rheumatoid arthritis or lupus: a critical review. Lupus 1996; 5 Suppl 1:S59.
- Choy EH, Hoogendijk JE, Lecky B, Winer JB. Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis. Cochrane Database Syst Rev 2005; :CD003643.
- Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet 2003; 362:971.
- Woo TY, Callen JP, Voorhees JJ, et al. Cutaneous lesions of dermatomyositis are improved by hydroxychloroquine. J Am Acad Dermatol 1984; 10:592.
- James WD, Dawson N, Rodman OG. The treatment of dermatomyositis with hydroxchloroquine. J Rheumatol 1985; 12:1214.
- Cosnes A, Amaudric F, Gherardi R, et al. Dermatomyositis without muscle weakness. Long-term follow-up of 12 patients without systemic corticosteroids. Arch Dermatol 1995; 131:1381.
- Dawkins MA, Jorizzo JL, Walker FO, et al. Dermatomyositis: a dermatology-based case series. J Am Acad Dermatol 1998; 38:397.
- Olson NY, Lindsley CB. Adjunctive use of hydroxychloroquine in childhood dermatomyositis. J Rheumatol 1989; 16:1545.
- Marmor MF, Kellner U, Lai TY, et al. Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision). Ophthalmology 2016; 123:1386.
- Jewell ML, McCauliffe DP. Patients with cutaneous lupus erythematosus who smoke are less responsive to antimalarial treatment. J Am Acad Dermatol 2000; 42:983.
- Rahman P, Gladman DD, Urowitz MB. Smoking interferes with efficacy of antimalarial therapy in cutaneous lupus. J Rheumatol 1998; 25:1716.
- Pelle MT, Callen JP. Adverse cutaneous reactions to hydroxychloroquine are more common in patients with dermatomyositis than in patients with cutaneous lupus erythematosus. Arch Dermatol 2002; 138:1231.
- Bloom BJ, Tucker LB, Klein-Gitelman M, et al. Worsening of the rash of juvenile dermatomyositis with hydroxychloroquine therapy. J Rheumatol 1994; 21:2171.
- Ang GC, Werth VP. Combination antimalarials in the treatment of cutaneous dermatomyositis: a retrospective study. Arch Dermatol 2005; 141:855.
- Michaelides M, Stover NB, Francis PJ, Weleber RG. Retinal toxicity associated with hydroxychloroquine and chloroquine: risk factors, screening, and progression despite cessation of therapy. Arch Ophthalmol 2011; 129:30.
- Zieglschmid-Adams ME, Pandya AG, Cohen SB, Sontheimer RD. Treatment of dermatomyositis with methotrexate. J Am Acad Dermatol 1995; 32:754.
- Metzger AL, Bohan A, Goldberg LS, et al. Polymyositis and dermatomyositis: combined methotrexate and corticosteroid therapy. Ann Intern Med 1974; 81:182.
- Kasteler JS, Callen JP. Low-dose methotrexate administered weekly is an effective corticosteroid-sparing agent for the treatment of the cutaneous manifestations of dermatomyositis. J Am Acad Dermatol 1997; 36:67.
- Hornung T, Ko A, Tüting T, et al. Efficacy of low-dose methotrexate in the treatment of dermatomyositis skin lesions. Clin Exp Dermatol 2012; 37:139.
- Femia AN, Vleugels RA, Callen JP. Cutaneous dermatomyositis: an updated review of treatment options and internal associations. Am J Clin Dermatol 2013; 14:291.
- Hoekstra M, Haagsma C, Neef C, et al. Bioavailability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritis. J Rheumatol 2004; 31:645.
- Vuong V, Duong TA, Aouizerate J, et al. Dermatomyositis: factors predicting relapse. J Eur Acad Dermatol Venereol 2016; 30:813.
- OVERVIEW OF CLINICAL FEATURES
- Impact on quality of life
- Disease course
- CLASSIFICATION OF CUTANEOUS DM
- Classic DM
- Amyopathic DM
- Hypomyopathic DM
- Postmyopathic DM
- PATIENT EVALUATION
- Indications for biopsy
- Additional tests
- Approach to treatment
- Interventions for pruritus
- Topical therapy
- - Topical corticosteroids
- - Topical calcineurin inhibitors
- - Other
- Systemic therapy
- - Approach to systemic therapy
- - First-line systemic therapy
- - Efficacy and administration
- - Adverse effects
- - Second-line systemic therapy
- - Efficacy and administration
- - Adverse effects
- RECURRENT AND RESISTANT DISEASE
- CALCINOSIS CUTIS
- SUMMARY AND RECOMMENDATIONS